参考文献/References:
[1] CantariniL, Lopalco G, Caso F, et al. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behcet’s disease[J]. Autoimmunity Reviews, 2015, 14(1): 1-9.
[2] Mendoza-Pinto C, Garcia-Carrasco M, Jimenez-Hernandez M, et al. Etiopathogenesis of Behcet’s disease[J]. Autoimmunity Reviews, 2010, 9(4): 241-245.
[3] Kapsimali V D, Kanakis M A, Vaiopoulos G A, et al. Etiopathogenesis of Behcet’s disease with emphasis on the role of immunological aberrations[J]. Clinical Rheumatology, 2010, 29(11): 1211-1216.
[4] Pineton de C M, Wechsler B, Geri G, et al. New insights into the pathogenesis of Behcet’s disease[J]. Autoimmunity Reviews, 2012, 11(10): 687-698.
[5] Emiroglu N, Cengiz F P, Erdem G B. Serum IL-17A in Behcet’s disease[J]. Postepy Dermatol Alergol, 2015, 32(5): 358-361.
[6] Zhou Zhenyuan, Chen S L, Shen Nan, et al. Cytokines and Behcet’s disease[J]. Autoimmunity Reviews, 2012, 11(10): 699-704.
[7] Xu Wangdong, Zhao Yi, Liu Yi. Insights into IL-37, the role in autoimmune diseases[J]. Autoimmunity Reviews, 2015, 14: 1170-1175.
[8] Hatemi G, Yazici Y, Yazici H. Behet’s syndrome[J]. Rheumatic Diseases Clinics of North America, 2013, 39(2): 245-261.
[9] Leng Ruixue, Chen Guimei, Pan Haifeng, et al. The role of IL-23/IL-17 axis in the etiopathogenesis of Behcet’s disease[J]. Clinical Rheumatology, 2010, 29(10): 1209.
[10] Touzot M, Cacoub P, Bodaghi B, et al. IFN-α induces IL-10 production and tilt the balance between Th1 and Th17 in Behet disease[J]. Autoimmunity Reviews, 2015, 14(5): 370-375.
[11] Vitale A, Rigante D, Lopalco G, et al. Interleukin-1 Inhibition in Behcet’s disease[J]. Israel Medical Association Journal, 2016, 18(3/4): 171-176.
[12] Chan E, Sangle S R, Coghlan J G, et al. Pulmonary artery aneurysms in Behcet’s disease treated with anti-TNFα: aa case series and review of the literature[J]. Autoimmunity Reviews, 2016, 15(4): 375-378.
[13] Ye Liang, Ji Ling, Wen Zhongyang, et al. IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity[J]. Journal of Translational Medicine, 2014, 12(1): 69.
[14] Wang Weiqing, Dong Kui, Zhou Lu, et al. IL-37b gene transfer enhances the therapeutic efficacy of mesenchumal stromal cells in DSS-induced colitis mice[J]. Acta Pharmacologica Sinica, 2015, 36(11): 1377-1387.
[15] Chen Bingni, Huang Kunzhao, Ye Liang, et al. Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity[J]. Journal of Translational Medicine, 2015, 13(1): 36.
[16] Bouali E, Kaabachi W, Hamzaoui A, et al. Interleukin-37 expression is decreased in Behcet’s disease and is associated with inflammation[J]. Immunology Letters, 2015, 167(2): 87-94.
相似文献/References:
[1]丁利平,刘冬舟,黎丽,等.脂多糖协同MSU诱导THP1分泌IL-1β和IL-18[J].深圳大学学报理工版,2016,33(6):566.[doi:10.3724/SP.J.1249.2016.06566]
Ding Liping,Liu Dongzhou,Li Li,et al.Synergistic action of LPS on production of IL-1β and IL-18 induced by MSU in THP1 cells[J].Journal of Shenzhen University Science and Engineering,2016,33(5):566.[doi:10.3724/SP.J.1249.2016.06566]